嵌合抗原受体修饰T细胞治疗前列腺癌的研究进展

Advances in the treatment of prostate cancer by chimeric antigen receptor modified T cells

嵌合抗原受体修饰T细胞(CAR-T)是近年来免疫治疗的热点,在血液系统疾病的治疗中取得了显著的临床疗效。目前,CAR-T在前列腺癌(PCa)治疗的研究中也取得了较大进展,其中以前列腺特异性膜抗原(PSMA)和前列腺干细胞抗原(PSCA)为靶点的CAR-T治疗进展较快,其可显著抑制肿瘤细胞生长,一定程度地延缓疾病进展。本文综述了前列腺肿瘤相关抗原(TAA)在前列腺癌CAR-T治疗中的最新研究进展,并对CAR-T在前列腺癌治疗中的挑战予以简要探讨,以期为临床提供参考。

The research of chimeric antigen receptor modification T cells(CAR-T)is a hotspot in immunotherapy in recent years,which has achieved remarkable clinical efficacy in the treatment of hematological diseases.At present,CAR-T has also made great progress in the treatment of prostate cancer(PCa).CAR-T therapy targeting prostate-specific membrane antigen(PSMA)and prostate-stem cell antigen(PSCA)has made rapid progresses,which can significantly inhibit tumor cell growth and delay disease progression in a certain extent.This article reviewed the recent clinical research progress of prostate cancer associated antigen(TAA)in the treatment of prostate cancer with CAR-T,and briefly discussed the challenges of CAR-T in the treatment of prostate cancer for better clinical application.